Tivic Health Partners with NIAID to Evaluate Entolimod for Radiation Syndrome

Key Facts

1Tivic Health Systems entered into an agreement with the NIAID to conduct preclinical studies evaluating Entolimod.

2The studies aim to evaluate the drug as a treatment for gastrointestinal acute radiation syndrome (GI-ARS).

3The Armed Forces Radiobiology Research Institute (AFRRI) will conduct the study sponsored by the NIAID.

Tivic Health Systems (Nasdaq: TIVC) has entered into a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID). The collaboration focuses on conducting preclinical studies to evaluate the drug candidate Entolimod as a medical countermeasure. Specifically, the studies aim to assess the drug's efficacy in treating gastrointestinal acute radiation syndrome (GI-ARS). The research will be conducted by the Armed Forces Radiobiology Research Institute (AFRRI) under the sponsorship of the NIAID. This partnership provides Tivic Health with significant government-backed resources and validation for its lead candidate. While the drug remains in the preclinical stage, the agreement marks a critical milestone in the company's clinical development strategy.